Cite
APA Citation
Rittmeyer, A., Felip, E., Altorki, N., Vallieres, E., Zhou, C., Martinez-Marti, A., Csoszi, T., Reck, M., Teixeira, M., Deng, Y., Huang, M., McNally, V., Bennett, E., Gitlitz, B., Srivastava, M., & Wakelee, H. (n.d.). 123P IMpower010: Exploratory overall survival (OS) with adjuvant atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression. Immuno-oncology technology, 16, . http://access.bl.uk/ark:/81055/vdc_100172068669.0x00000b